Award

Program Details

Lena Gray, P.T. &

Baby Development Expert

M E D I C I N E S    D I S C O V E R Y    A W A R D    P R O G R A M

  • $100,000 up to $7.5M in program support over five years (reviewed annually)

  • Access to EDI’s Scientific Advisory Board, strategic partners & consultant network

  • Drug discovery and development expertise

  • Project management & planning

  • Business and commercialization advice

  • Assistance in company incorporation & management

  • Clinical development advice

  • Regulatory strategy & IND preparation assistance

  • IP review and filing support

  • Assistance identifying and securing additional finance (based on program needs)

EDI and the Scientific Advisory Board will work closely with the awardee and their affiliated institution to maximize the clinical and commercial potential of the selected program.

S E L E C T I O N     C R I T E R I A

EDI is interested in programs that provide novel insights into the pathways and molecular determinants of human disease.  We prefer programs that have a clear mechanism of action or possess a well-defined genetic basis for the underlying condition and projects with a strong biomarker component are highly desirable.  EDI is open to applications across a wide range of therapeutic areas providing a strong scientific, medical and commercial rationale can be made. Programs in the fields of cancer, neurological diseases/CNS conditions and platform technologies with therapeutic potential across multiple diseases are of particular interest.  Investigators working in the rare and orphan diseases are also encouraged to apply.

Qualifying programs should (at a minimum) have data to support the selection and validation of the proposed target.  EDI will support the advancement of selected programs from the “Target to Hit” stage to “IND-ready” programs for entry into human clinical trials. This is a step-wise program that is anticipated to take approximately 5 years to advance a molecule from Stage 2 (Target to Hit) to Stage 5 (Pre-Clinical Development) with the completion of IND-enabling regulatory studies to facilitate clinical testing. 

Ideally, the program should have the potential for the creation of new and novel “composition of matter” patents.  We are agnostic to the therapeutic modality and we are open to programs that are based on the development of small molecules, biologics (peptides, proteins, antibodies), oligonucleotide (RNA, DNA based therapies), vaccines, gene and cell based therapies.  We do not currently support the development of diagnostic products or medical devices.  

A P P L I C A T I O N     P R O C E S S

Are you Ready to Apply?

The 2019 EDI Medicines Award Program is now open.  Applications will be accepted and reviewed on a rolling basis until the November 29th 2019 submission deadline.

 

Two application opportunities will be announced each year.  Investigators holding a full-time position at the University of Rochester, University at Buffalo and Roswell Park Comprehensive Cancer Center are eligible to apply and must be submitted by the posted deadline on the application form. 

The SAB will review applications and investigators with a program of interest will be invited to make a 30 minute presentation to the selection board before a final decision for support is made.  

 

EDI and the Scientific Advisory Board will work closely with the awardee and their affiliated institution to maximize the clinical and commercial potential of the selected program.

logo final_.png

Contact Us 

601 Elmwood Ave, Box EDI

Rochester, NY 14642

(585) 276-3150

Email info@discoveredi.org